Rabbit Recombinant Monoclonal DRAK2 antibody. Carrier free. Suitable for ICC/IF, IP, WB and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: PBS
ICC/IF | IP | WB | |
---|---|---|---|
Human | Tested | Tested | Tested |
Mouse | Expected | Expected | Tested |
Rat | Expected | Expected | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Human, Mouse | Dilution info - | Notes - |
Phosphorylates myosin light chains (By similarity). Acts as a positive regulator of apoptosis.
DRAK2, STK17B, Serine/threonine-protein kinase 17B, DAP kinase-related apoptosis-inducing protein kinase 2
Rabbit Recombinant Monoclonal DRAK2 antibody. Carrier free. Suitable for ICC/IF, IP, WB and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: PBS
ab201323 is the carrier-free version of Anti-DRAK2 antibody [EPR3163Y] ab108373.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
DRAK2 also known as Death-associated protein kinase-related apoptosis-inducing protein kinase 2 is part of the serine/threonine kinase family. This protein has a molecular weight of about 48 kDa. DRAK2 expresses mostly in lymphoid tissues including the spleen and thymus. It plays a role in negative regulation during T-cell receptor signaling and is important during lymphocyte activation.
The role of DRAK2 extends beyond kinase activity. It is involved in immune response modulation and can affect apoptosis in T lymphocytes. DRAK2 is not part of a larger protein complex but rather acts independently to exert its function. It influences cellular mechanisms by altering signaling pathways that impact cell survival and death.
You find DRAK2 involved in both the T-cell receptor signaling and apoptosis pathways. It connects to the T-cell receptor pathway due to its regulation of T-cell activation and proliferation. DRAK2 activity can interact with proteins such as calmodulin and Protein Kinase C in these pathways indicating its role in signaling transduction critical for T-cell function.
DRAK2 links to autoimmune diseases and cancer. Abnormal DRAK2 expression might contribute to autoimmune conditions like multiple sclerosis by affecting T-cell autoreactivity. Its involvement in cancer emerges through regulation of apoptosis where malfunction may lead to resistance against cell death aiding cancer cell survival. In this context DRAK2 connection with proteins such as caspases plays a role in mediating apoptotic pathways in cells.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-DRAK2 antibody [EPR3163Y] ab108373, the same antibody clone in a different buffer formulation.
Lane 1 Wild-type HAP1 cell lysate (20 Âμg)
Lane 2 DRAK2 knockout HAP1 cell lysate (20 Âμg)
Lane 3 Ramos cell lysate (20 Âμg)
Lane 4 Raji cell lysate (20 Âμg)
Lanes 1 - 4 Merged signal (red and green). Green - Anti-DRAK2 antibody [EPR3163Y] ab108373 observed at 42 kDa. Red - loading control, Anti-GAPDH antibody [6C5] - Loading Control ab8245, observed at 37 kDa.
Anti-DRAK2 antibody [EPR3163Y] ab108373 was shown to recognize DRAK2 when DRAK2 knockout samples were used, along with additional cross-reactive bands. Wild-type and DRAK2 knockout samples were subjected to SDS-PAGE. Anti-DRAK2 antibody [EPR3163Y] ab108373 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (loading control to GAPDH) were diluted 1/500 and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD)preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1/10000 dilution for 1 h at room temperature before imaging.
All lanes: Western blot - Anti-DRAK2 antibody [EPR3163Y] (Anti-DRAK2 antibody [EPR3163Y] ab108373)
Predicted band size: 42 kDa
This data was developed using Anti-DRAK2 antibody [EPR3163Y] ab108373, the same antibody clone in a different buffer formulation.Immunofluorescence staining of Ramos cells with purified Anti-DRAK2 antibody [EPR3163Y] ab108373 at a working dilution of 1/100, counter-stained with DAPI. The secondary antibody was Alexa Fluor® 488 goat anti-rabbit (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077), used at a dilution of 1/1000. Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291, a mouse anti-tubulin antibody (1/1000), was used to stain tubulin along with Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120 (Alexa Fluor® 594 goat anti-mouse, 1/1000), shown in the top right hand panel. The cells were fixed in 4% PFA and permeabilized using 0.1% Triton X 100. The negative controls are shown in bottom middle and right hand panels - for negative control 1, purified Anti-DRAK2 antibody [EPR3163Y] ab108373 was used at a dilution of 1/500 followed by an Alexa Fluor® 594 goat anti-mouse antibody (Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120) at a dilution of 1/500. For negative control 2, Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 (mouse anti-tubulin) was used at a dilution of 1/500 followed by an Alexa Fluor® 488 goat anti-rabbit antibody (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) at a dilution of 1/400.
This data was developed using Anti-DRAK2 antibody [EPR3163Y] ab108373, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
All lanes: Western blot - Anti-DRAK2 antibody [EPR3163Y] (Anti-DRAK2 antibody [EPR3163Y] ab108373) at 1/1000 dilution
Lane 1: C6 whole cell lysate at 10 µg
Lane 2: PC-12 whole cell lysate at 10 µg
Lane 3: NIH/3T3 whole cell lysate at 10 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 42 kDa, 59 kDa
Observed band size: 42 kDa
This data was developed using Anti-DRAK2 antibody [EPR3163Y] ab108373, the same antibody clone in a different buffer formulation.Anti-DRAK2 antibody [EPR3163Y] ab108373 (purified) at 1/40 immunoprecipitating DRAK2 in 10 μg Ramos cell lysate (Lanes 1 and 2, observed at 42 kDa). Lane 3 - Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730). For western blotting, VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366), was used for detection at 1/10,000 dilution. Blocking buffer and concentration: 5% NFDM/TBST Dilution buffer and concentration: 5% NFDM/TBST
All lanes: Immunoprecipitation - Anti-DRAK2 antibody [EPR3163Y] (Anti-DRAK2 antibody [EPR3163Y] ab108373)
Predicted band size: 39 kDa, 42 kDa
This data was developed using Anti-DRAK2 antibody [EPR3163Y] ab108373, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
All lanes: Western blot - Anti-DRAK2 antibody [EPR3163Y] (Anti-DRAK2 antibody [EPR3163Y] ab108373) at 1/10000 dilution
Lane 1: Ramos whole cell lysate at 10 µg
Lane 2: Raji whole cell lysate at 10 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 42 kDa
Observed band size: 42 kDa
This data was developed using Anti-DRAK2 antibody [EPR3163Y] ab108373, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-DRAK2 antibody [EPR3163Y] (Anti-DRAK2 antibody [EPR3163Y] ab108373) at 1/500 dilution
Lane 1: Jurkat cell lysate +TPA at 10 µg
Lane 2: Ramos cell lysate at 10 µg
Lane 3: Ramos cell lysate + TPA at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 42 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com